<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melanoma in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melanoma in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Melanoma in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elena B Hawryluk, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alberto S Pappo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ashfaq A Marghoob, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Armita Bahrami, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 22, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H51145243"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pediatric melanoma, usually defined as melanoma occurring in patients younger than 20 years, is rare, accounting for approximately 1 percent of all melanomas [<a href="#rid1">1,2</a>]. Because of its rarity, the biology and clinical behavior, as well as the histopathologic features of pediatric melanoma, are not well characterized. The diagnosis is often extremely difficult to establish, especially in prepubertal children in whom melanoma may present as a nonspecific, amelanotic lesion with a morphology resembling a benign growth, resulting in frequent misdiagnosis, delays in diagnosis, thicker tumors, and delayed treatment [<a href="#rid3">3</a>].</p><p>This topic will discuss the clinical presentation, diagnosis, and management of melanoma in children. Melanoma in adults is discussed separately. Spitz nevi and atypical Spitz tumors are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p></p><p class="headingAnchor" id="H51145249"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The term "juvenile melanoma" is only of historical relevance. Introduced by Sophie Spitz in 1948, it describes childhood melanocytic lesions with histologic features of melanomas but less aggressive clinical behavior compared with adult melanomas [<a href="#rid4">4</a>]. These lesions remain distinct from banal nevi and conventional melanoma and are now collectively regarded as Spitz tumors, a disease spectrum including benign Spitz nevi, spitzoid melanomas, and variants with uncertain malignant potential. These lesions are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p class="headingAnchor" id="H51145255"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H26420266"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Melanoma is rare in individuals younger than 20 years, with an estimated annual incidence rate of nine per million in those aged 15 to 19 years, according to the Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review 1975-2014 [<a href="#rid5">5</a>]. Melanoma is even rarer in younger children, with estimated annual incidence rates of one, two, and three per million in the age groups 1 to 4, 5 to 9, and 10 to 14, respectively [<a href="#rid5">5</a>]. Lower incidence rates of pediatric melanoma have been reported among Hispanic and American Indian children &lt;19 years (2.1 and 3.3 per million individuals, respectively) [<a href="#rid6">6</a>]. Due to the low incidence and lack of comprehensive registries, the precise incidence of clinical subtypes of pediatric melanoma, such as congenital and infantile melanoma, melanoma associated with congenital nevi, or spitzoid melanoma, is unknown.</p><p>Progressive increases in melanoma incidence in children have been reported in the United States over the last few decades, with approximately 90 percent of cases occurring among children older than 10 years [<a href="#rid1">1,7</a>]. However, one study utilizing SEER data from 2000 to 2010 has reported the first decrease in age-adjusted incidence rates of melanoma in children and adolescents in the United States [<a href="#rid8">8</a>]. In this report, the decrease in incidence was most notable between 2003 and 2010 among adolescents aged 15 to 19 years. This finding is consistent with trends in Australia and Sweden, where reductions in pediatric melanoma incidence have also been reported [<a href="#rid9">9,10</a>]. This decrease may be related to improved awareness regarding melanoma, changes in sun protection practices, and restricting indoor tanning access for minors. However, it is also possible that the decreased incidence of pediatric melanoma may be due, in part, to the improved histopathologic and molecular classification of some benign lesions (eg, some Spitz nevi and proliferative nodules in giant congenital nevi) that were misdiagnosed as melanomas in the past. Ongoing data collection and analysis are necessary to determine the cause for this apparent decline in incidence and whether this trend will persist.</p><p class="headingAnchor" id="H26420118"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Risk factors for adult melanoma are also significant for pediatric patients. They include genetic factors (eg, family history of melanoma, light skin phenotype and propensity to sunburn, high nevus counts, congenital nevi, inherited deoxyribonucleic acid [DNA] repair defects), environmental factors (eg, excessive exposure to sunlight, history of sunburns, indoor tanning), and iatrogenic or acquired immunosuppression. In a cohort of 70 pediatric patients with melanoma, 40 percent had high nevus counts, 27 percent had a positive family history of melanoma, and 25 percent reported a history of sunburn [<a href="#rid11">11-13</a>].</p><p>Variants of the melanocortin-1 receptor (<em>MC1R</em>) gene, a key regulator of skin pigmentation, are likely genetic risk factors for melanoma in children and adolescents.</p><p class="bulletIndent1"><span class="glyph">●</span>In a multicenter, case-control study including 233 children/adolescents (≤20 years) and 932 adults with melanoma and 932 controls, children and adolescents with melanoma had higher frequencies of any <em>MC1R</em> variants, r variants, V60L variants, and D294H variants than adults with melanoma and unaffected controls [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an Italian cohort of 123 patients younger than 21 years with histologically confirmed melanoma (116 conventional melanomas, 4 spitzoid, and 3 of other type), <em>MC1R </em>pathogenic variants were found in 67 percent of patients, whereas pathogenic variants affecting <em>CDKN2A</em> were extremely rare in sporadic cases (2 percent) [<a href="#rid15">15</a>].</p><p></p><p>Other risk factors include hereditary retinoblastoma and Werner syndrome [<a href="#rid12">12,16</a>]. (See  <a class="medical medical_review" href="/z/d/html/6275.html" rel="external">"Retinoblastoma: Clinical presentation, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/106742.html" rel="external">"Werner syndrome"</a>.)</p><p class="headingAnchor" id="H400166901"><span class="h2">Melanoma arising in congenital nevi</span><span class="headingEndMark"> — </span>A systematic review of melanoma in patients with congenital melanocytic nevi of any size found a mean age at diagnosis of 15.5 years (median 7 years) and estimated a 465-fold higher risk of developing melanoma in childhood or adolescence for patients with congenital nevi compared with the general population [<a href="#rid17">17</a>]. It should be underscored that while most of these melanomas developed within large congenital nevi (67 percent), approximately 8 percent of primary melanomas developed in extracutaneous sites, including the central nervous system in patients with neurocutaneous melanocytosis. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi", section on 'Neurocutaneous melanosis'</a>.)</p><p>The risk of melanoma is not evenly distributed across all congenital nevi since the magnitude of risk correlates with congenital nevus size and number. The lifetime risk for the development of melanoma within a small congenital nevus (&lt;1.5 cm adult diameter) to medium-sized congenital nevus (1.5 to 20 cm adult diameter) is less than 1 percent [<a href="#rid18">18</a>]. Children with large congenital nevi (&gt;20 cm adult diameter) have a slightly increased risk of developing melanoma, estimated to be between 2 and 10 percent [<a href="#rid19">19</a>]. Patients with giant congenital nevi (&gt;40 cm adult diameter) and multiple satellites (multiple small congenital nevi) represent the highest risk group, with a lifetime risk as high as 12 percent for developing cutaneous or extracutaneous melanoma [<a href="#rid19">19-22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi"</a>.)</p><p>In a 2013 meta-analysis of 14 studies including 2578 patients with large congenital melanocytic nevi, melanoma developed in 51 patients (2 percent) at a mean age of 13 years (range 0 to 58 years), with a mortality rate of 55 percent [<a href="#rid19">19</a>]. Most melanomas developed in giant congenital nevi or in large congenital nevi associated with multiple satellite nevi [<a href="#rid19">19</a>].</p><p>Melanomas developing in patients with congenital melanocytic nevi may arise in the skin, the central nervous system, or in other extracutaneous locations. In an analysis of a United Kingdom cohort of 448 children with congenital melanocytic nevi observed between 1988 and 2016, 12 children (2.7 percent) developed a melanoma [<a href="#rid23">23</a>]. Of these 12 primary melanomas, seven were primary melanomas of the central nervous system, two were primary cutaneous, one was primarily lymph nodal, and two were melanomas with unknown primary. The authors found that an abnormal screening magnetic resonance imaging (MRI) of the central nervous system in the first year of life in these patients was associated with a higher melanoma risk compared with a normal screening MRI (12 versus 2 percent, respectively). (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi", section on 'Neurocutaneous melanosis'</a>.)</p><p class="headingAnchor" id="H3997827419"><span class="h2">Spitzoid melanoma</span><span class="headingEndMark"> — </span>Spitzoid melanomas are predominantly seen in preadolescent children [<a href="#rid24">24-26</a>]. In clinical practice, the choice of treatment is made based upon the lesion size and type (eg, homogeneous versus nonhomogeneous), presence and grade of histopathologic dysplasia, patient's preference, and clinical experience [<a href="#rid27">27</a>]. These lesions have histologic features of Spitz tumors; those with characteristic genetic alterations of Spitz tumors, such as activating <em>HRAS</em> mutations or kinase fusions, are termed "Spitz melanomas" [<a href="#rid28">28,29</a>].</p><p>Spitzoid melanoma in children has clinicopathologic features, biologic behavior, and a prognosis distinct from adult-type spitzoid melanoma.</p><p class="bulletIndent1"><span class="glyph">●</span>A multisite investigation spanning over two decades in 12 large academic institutions did not identify any fatal cases of spitzoid melanoma in prepubertal children [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, there were no fatal outcomes among the Spitz melanomas and atypical Spitz tumors reported in the 2022 prospective registry Molecular Analysis of Childhood Melanocytic Tumors, which integrates molecular analysis of pediatric melanomas [<a href="#rid31">31</a>].</p><p></p><p>The clinical features, diagnosis, and management of atypical Spitz tumors are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors", section on 'Spitz melanoma'</a>.)</p><p class="headingAnchor" id="H26420254"><span class="h2">Congenital and infantile melanoma</span><span class="headingEndMark"> — </span>Congenital and infantile melanoma, defined as melanoma present at birth or developing in the first year of life, is exceedingly rare, with only a few cases reported in the literature [<a href="#rid32">32</a>]. In a retrospective review of 87 women with placental or fetal metastases, 27 cases were attributed to melanoma [<a href="#rid33">33</a>]. The fetus was affected in six cases, and five of six infants succumbed to disease. In one report of transplacental metastasis of terminal maternal melanoma, the infant experienced spontaneous regression of all lesions and was disease free at the time of the report publication [<a href="#rid34">34</a>].</p><p>There are no long-term follow-up data on unaffected children born to mothers with metastatic melanoma to exclude the possibility of a delayed presentation of the disease. However, neonates who do not present melanoma metastases at birth should be considered at high risk and undergo close clinical monitoring. Some experts recommend repeated clinical evaluation during the first year of life and even beyond. Pathologic examination of the placenta for melanoma is also warranted in these cases.</p><p class="headingAnchor" id="H51145261"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Pediatric melanoma is considered to be biologically distinct from adult melanoma due to several distinctive features: greater thickness at presentation, higher frequency of amelanotic lesions, greater rate of sentinel node positivity, and overall less aggressive clinical course [<a href="#rid3">3</a>]. Whether the greater thickness at presentation is due to delayed diagnosis or more rapid growth in children has not been determined.</p><p>Congenital melanoma can arise de novo, in association with a congenital nevus, or from transplacental metastases from metastatic maternal melanoma. The pathophysiology of transplacental spread of melanoma is unclear. Factors involved may include the high vascularity of the placenta, placental production of angiogenic and growth factors, and impaired fetal immune response.</p><p>Molecular testing has provided insights in the molecular pathogenesis of pediatric melanoma. The results of a study of whole-genome or whole-exome sequencing and targeted sequencing of 23 pediatric melanoma samples, including 15 conventional (superficial spreading and nodular) melanomas, 3 melanomas associated with congenital nevi, and 5 spitzoid melanomas, are summarized below [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional melanomas (ie, superficial spreading and nodular) from 15 adolescent patients aged 10 to 20 years, 10 of whom died of disease, were histologically similar to adult melanoma and showed a high burden of somatic single nucleotide mutations, of which over 80 percent were consistent with ultraviolet radiation (UVR) damage. The activating <em>BRAF </em>V600 mutation was found in 13 of 15 patients (87 percent) and <em>TERT </em>promoter mutations in 12 of 13 patients. Alterations (deletion or inactivating mutation) were common in tumor suppressor genes <em>CDKN2A</em> (mutation in 15 percent and biallelic deletion in 21 percent) and <em>PTEN</em> (mutation in 23 percent and biallelic deletion in 14 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All three melanomas associated with congenital nevi had <em>NRAS </em>(but not <em>BRAF</em> or <em>TERT</em> promoter)<em> </em>mutations, which is not surprising, based on the known <em>NRAS </em>mutant status of most large and giant congenital nevi [<a href="#rid36">36</a>]. Although the size of the three congenital nevi was not reported, their mutation profile and the fact that all children were &lt;5 years of age and had a fatal outcome suggest that the congenital nevi were likely large lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two of the five spitzoid melanomas (from three preadolescent children, one adolescent, and one patient of borderline age, of whom one succumbed to disease) demonstrated kinase fusions but not <em>BRAF</em>/<em>NRAS</em> mutations. In other reports, kinase fusions that include <em>MAP3K8</em>, <em>ALK</em>, <em>NTRK1</em>,<em> NTRK3</em>, <em>MET</em>, <em>RET</em>, <em>ROS1</em>, and <em>BRAF </em>have been found with variable frequency.<em> </em>Of note, kinase fusions have also been identified in a significant number of banal Spitz nevi and atypical Spitz tumors [<a href="#rid37">37-40</a>].</p><p></p><p>Similar results were seen in another whole genome sequencing study of tumor samples from 50 adolescent and young adult patients with melanoma (superficial spreading in 43 of 50 patients) [<a href="#rid41">41</a>]. Patients ranged from age 10 to 30, with a median age of 20 years, and had stage III/IV melanoma. Melanomas showed a high mutation burden, with <em>BRAF</em> mutations being present in 96 percent of cases, 82 percent of which were p.V600E. <em>TERT</em> was the second most frequently mutated gene, with promoter hotspot mutations present in 80 percent of cases, followed by <em>PTEN</em> (36 percent), <em>CDKN2A</em> (24 percent), <em>TP53</em> (24 percent), and <em>RBI</em> (12 percent). Ninety percent of the mutations found were UVR signature mutations.</p><p>These findings suggest that conventional melanoma in adolescents is similar to <em>BRAF</em>-mutant adult melanoma and confirm that UVR is likely a major mutagenic factor in melanomas occurring in adolescence. Melanomas associated with congenital nevi and spitzoid melanomas are instead distinct entities, with a different genetic profile, clinical course, and prognosis. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors", section on 'Spitz melanoma'</a> and  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors", section on 'Mutational analysis'</a>.)</p><p class="headingAnchor" id="H26420241"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The clinical presentation of melanoma in children often does not conform to the conventional ABCDE criteria (<strong>a</strong>symmetry, <strong>b</strong>order irregularities, <strong>c</strong>olor variegation, <strong>d</strong>iameter ≥6 mm, <strong>e</strong>volving lesion)  (<a class="graphic graphic_picture graphicRef105746" href="/z/d/graphic/105746.html" rel="external">picture 4B</a>). Especially in prepubertal children, melanoma may present as a symmetric, pigmented lesion with regular borders simulating a banal nevus; as a pink or reddish, symmetric, dome-shaped papule simulating a Spitz nevus  (<a class="graphic graphic_picture graphicRef105749" href="/z/d/graphic/105749.html" rel="external">picture 1</a>); or as an amelanotic, nodular lesion simulating a pyogenic granuloma  (<a class="graphic graphic_picture graphicRef105751" href="/z/d/graphic/105751.html" rel="external">picture 2</a>) or common wart. Lesions may be uniform in color and smaller than 6 mm. Most importantly, the "evolving lesion" criterion of the ABCDE rule is not as helpful in children and adolescents, in whom the onset of new nevi as well as lesion evolution (ie, increase in diameter and elevation) are the rule.</p><p>In a series of 70 children with melanoma, 60 percent of lesions in children &lt;11 years and 40 percent of those in adolescents lacked the conventional ABCDE criteria [<a href="#rid11">11</a>]. Lesions were more likely to be small and amelanotic in young children and frequently uniform in color in adolescents, with lesion evolution being a nearly universal finding.</p><p>In a study of 52 pediatric melanoma cases [<a href="#rid42">42</a>], approximately 52 percent of lesions manifested the conventional ABCD criteria. However, the clinical morphology differed significantly between cases of spitzoid melanoma and nonspitzoid melanomas. While less than 25 percent of all cases of pediatric melanoma (spitzoid and nonspitzoid) fulfilled the modified ABCD criteria (<strong>a</strong>melanotic, <strong>b</strong>leeding/<strong>b</strong>ump, <strong>c</strong>olor uniformity, <strong>d</strong>e novo/any <strong>d</strong>iameter), 40 percent of the spitzoid and only 13.5 percent of nonspitzoid melanoma cases revealed the modified ABCD features (see <a class="local">'Physical examination'</a> below). In contrast, almost 60 percent of nonspitzoid melanoma cases and only 33 percent of spitzoid melanoma cases had the conventional ABCD features.</p><p>In another series of pediatric melanomas, the prebiopsy clinical diagnosis was a benign lesion in 40 of 68 cases (59 percent) and atypical nevus or melanoma in 28 [<a href="#rid43">43</a>]. Forty-five percent of the tumors were amelanotic, and the most common presentation sign was a change in size and color. Pediatric melanomas that mimicked benign-appearing lesions were more likely to have a Breslow thickness &gt;1 mm (odds ratio 5.48, 95% CI 1.66-20.12).</p><p>The atypical appearance of pediatric melanomas can cause a diagnostic challenge, leading to a delay in diagnosis and thicker lesions  (<a class="graphic graphic_picture graphicRef105752" href="/z/d/graphic/105752.html" rel="external">picture 3</a>). In one study of 70 pediatric melanoma cases, the time from detection to diagnosis was ≥6 months in 82 percent and &gt;12 months in 62 percent of patients, and, in keeping with the diagnostic delay, more than 90 percent of childhood cases and 50 percent of adolescent cases were diagnosed with stage IIa disease or higher [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H51145273"><span class="h1">DERMOSCOPIC FEATURES</span><span class="headingEndMark"> — </span>Dermoscopy has emerged as a useful tool to differentiate the morphology of various pediatric skin lesions that resemble melanoma. Evaluation using a dermatoscope is painless and well tolerated by children in the clinic [<a href="#rid44">44</a>].</p><p>Ten melanoma-specific dermoscopic structures have been identified: atypical network; negative network; streaks; shiny, white structures; atypical dots and globules; irregular blotch; blue-white veil; regression structures; peripheral, brown, structureless areas; and atypical vessels. The presence of at least 1 of these 10 structures should raise suspicion of melanoma. Since melanomas in children are often amelanotic, the examination of vascular structures and presence of shiny, white structures is of primary importance  (<a class="graphic graphic_table graphicRef79290" href="/z/d/graphic/79290.html" rel="external">table 1</a>). Any nodular, pink lesion with dotted vessels; milky, red globules; serpentine vessels; shiny, white structures seen with polarized light dermoscopy; or negative (inverse) network should be considered suspicious for melanoma. (See  <a class="medical medical_review" href="/z/d/html/13522.html" rel="external">"Dermoscopic evaluation of skin lesions", section on 'Criteria for melanoma'</a>.)</p><p>However, it is important to acknowledge that many of the dermoscopic features observed in melanoma can also be seen in Spitz nevi, making the clinical differential diagnosis between Spitz nevi and melanoma challenging.</p><p>An analysis of 49 dermoscopic images from 52 pediatric melanoma cases (mean age, range 2 to 20) found that the dermoscopic patterns most frequently associated with nonspitzoid melanomas were the multicomponent pattern and nevus-like pattern (58 and 25 percent, respectively) [<a href="#rid42">42</a>]. The multicomponent pattern is the "classic" dermoscopic melanoma pattern encountered in superficial spreading-type melanoma, with most cases presenting with a disorganized distribution of dots/globules, atypical network, blue-white veil, vessels, and negative network. Spitzoid melanomas showed in most cases a "vascular, pink, Spitz-like pattern" with atypical vessels and shiny, white structures or a "pigmented, Reed-like" pattern with black, blue-gray, and dark brown colors, peripheral streaks, and dark blotches. In this study, all cases of melanoma revealed at least one of the melanoma-specific structures.</p><p>However, even in the absence of melanoma-specific structures and atypical vascular morphology, all lesions that do not manifest an unequivocal benign pattern and lesions that appear atypical should be considered for histopathologic examination. A useful approach may also include measurement, photography, and close clinical follow-up for evaluation of lesion evolution.</p><p class="headingAnchor" id="H306101450"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of melanoma in children is challenging due to its rarity and often banal clinical presentation. It requires a high index of suspicion based upon history, clinical, and dermoscopic findings, as well as a low threshold for the decision to perform a biopsy. The definitive diagnosis is reliant upon histopathologic evaluation.</p><p class="headingAnchor" id="H1775114"><span class="h2">History</span><span class="headingEndMark"> — </span>A prominent feature in pediatric melanoma is lesion evolution over time. However, melanoma evolution in children may be misinterpreted as the expected and natural evolution of benign, pigmented lesions during childhood and adolescence. Patients or parents/caregivers may report a history of bleeding, particularly for ulcerated lesions. Additional complaints may include pain, itch, or discomfort, all of which can prompt evaluation in the clinic. Moreover, patients and parents/caregivers should be queried for recent treatments (eg, wart removal preparations) or trauma, as melanoma may have been misdiagnosed and treated as a benign entity.</p><p class="headingAnchor" id="H1775120"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>In older adolescents and young adults, most melanomas are of the nonspitzoid variety, and most of these will manifest the conventional "ABCDE criteria" (<strong>a</strong>symmetry, <strong>b</strong>order irregularity, <strong>c</strong>olor variegation, large <strong>d</strong>iameter, <strong>e</strong>volving lesion). In contrast, melanomas in prepubertal and pubertal children are often of the spitzoid melanoma type, and many of these will lack the conventional ABCD features. In addition, the "evolving lesion" criterion may not be helpful at an age in which the new onset/evolution of common nevi is normal. Additional sets of pediatric criteria (the pediatric ABCD and the CUP criteria) have therefore been proposed to be used <strong>in combination with</strong> the conventional ABCDE rule [<a href="#rid11">11,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A = <strong>A</strong>melanotic</p><p class="bulletIndent1"><span class="glyph">●</span>B = <strong>B</strong>leeding, <strong>b</strong>ump</p><p class="bulletIndent1"><span class="glyph">●</span>C = <strong>C</strong>olor uniformity</p><p class="bulletIndent1"><span class="glyph">●</span>D = <strong>D</strong>e novo, any <strong>d</strong>iameter</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C = <strong>C</strong>olor is pink/red, <strong>c</strong>hanging</p><p class="bulletIndent1"><span class="glyph">●</span>U = <strong>U</strong>lceration, <strong>u</strong>pward thickening</p><p class="bulletIndent1"><span class="glyph">●</span>P = <strong>P</strong>yogenic granuloma-like lesions, <strong>p</strong>op-up of new lesions</p><p></p><p>While these additional criteria may increase sensitivity for melanoma detection, they are <strong>not</strong> specific for melanoma. In a study of 52 pediatric melanoma cases, of which 15 were spitzoid and 37 nonspitzoid melanomas, only 40 percent of spitzoid melanomas and 13 percent of nonspitzoid melanomas fulfilled the proposed pediatric ABCD criteria [<a href="#rid42">42</a>].</p><p>When assessing a new pink/red papule in a child, it is important to also consider associated features, such as bleeding, history of trauma, itch or pain, growth or change over time, or similar lesions elsewhere, in the decision of whether to clinically monitor or biopsy a particular lesion.</p><p>If a lesion suspicious for melanoma is found on skin examination, palpation of the regional lymph nodes should be performed to evaluate for enlarged nodes. Additionally, evaluation of congenital nevi should include palpation for subcutaneous changes, especially in large congenital nevi since melanomas arising in large congenital nevi often develop below the dermo-epidermal junction.</p><p class="headingAnchor" id="H306101457"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>Biopsy is warranted when there is clinical suspicion of melanoma. An excisional biopsy including the subcutaneous fat with a small (2 mm) rim of normal-appearing skin is the preferred biopsy method. While incisional biopsy, including deep shave biopsy, is acceptable (especially if the lesion is large and/or in a cosmetically sensitive area), superficial shave biopsies should be avoided since the full depth of the lesion is required to accurately determine the degree of maturation of the melanocytes, evaluate the base of the lesion, and obtain an accurate measure of tumor thickness.</p><p class="headingAnchor" id="H1674372794"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>Not only are pediatric melanomas difficult to diagnose clinically, but they may also be challenging histopathologically. It can be difficult to distinguish a spitzoid melanoma from an atypical Spitz tumor because they have similar architectural and cytologic features, although the number and severity of atypical features are increased for melanomas  (<a class="graphic graphic_picture graphicRef105749" href="/z/d/graphic/105749.html" rel="external">picture 1</a>). For example, a large lesion diameter (especially &gt;1 cm), increased mitotic rate (especially &gt;6 per mm<sup>2</sup>), high cellular density, and ulceration raise concern for malignancy in Spitz tumors. Moreover, there are pigmented tumors of uncertain malignant potential, and there are challenging pigmented lesions for which expert dermatopathologists cannot reach consensus on a diagnosis [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors", section on 'Histopathology'</a>.)</p><p>Data on the frequency of each of the histologic subtypes of pediatric melanoma have not collected systematically, but it is estimated that approximately 40 to 50 percent of pediatric melanomas are of the conventional subtype (adult melanoma-like), which shares similar morphologic features with adult cutaneous melanoma (ie, superficial spreading and nodular) [<a href="#rid47">47</a>]. The same criteria for the histologic diagnosis, classification, and stage grouping for adult melanoma are applied to the pediatric conventional subtype. The affected individuals typically are adolescents or postpubertal children. Lentigo maligna melanoma (the histologic subtype that typically arises on chronically sun-damaged skin) almost never occurs in children/adolescents, and acral lentiginous melanoma (melanoma on glabrous skin) is exceedingly rare in this population [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p>Among pediatric melanomas, childhood tumors may show more aggressive histopathologic features than adolescent tumors  (<a class="graphic graphic_picture graphicRef105715 graphicRef105746" href="/z/d/graphic/105715.html" rel="external">picture 4A-B</a>), despite a paradoxically better survival [<a href="#rid11">11</a>]. A retrospective review of published fatal pediatric melanomas reported that childhood melanomas (up to age 10 years) were thicker than adolescent melanomas, with a mean Breslow thickness of 8.5 mm compared with adolescent melanoma mean Breslow thickness of 3.7 mm [<a href="#rid49">49</a>]. In another cohort of 12 children and 20 adolescents with melanoma, the median Breslow thickness was 3.5 mm for lesions in children versus 1.5 mm in adolescents [<a href="#rid24">24</a>]. In another series of 25 fatal cases of pediatric melanoma, the median Breslow thickness was 2.2 mm, with a range of 0.9 to 36 mm [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H306101463"><span class="h2">Molecular tests</span><span class="headingEndMark"> — </span>Genomic criteria (eg, multiple chromosomal copy number variations observed by comparative genomic hybridization [CGH] or fluorescence in situ hybridization [FISH]) and alterations in the <em>TERT</em> promoter [<a href="#rid25">25,37</a>] may provide support for the diagnosis of melanoma in atypical melanocytic proliferations. Laboratory diagnostic approaches, including FISH, CGH, and genomic sequencing, promise to further our understanding and diagnosis of these lesions, but studies have provided inconsistent results for pediatric tumors. Although histopathology continues to play an important role in the diagnosis of pediatric melanocytic lesions, integration of genomic findings improves the accurate pathologic classification of these lesions, which may ultimately affect the clinical management of these patients [<a href="#rid31">31,50,51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Next-generation sequencing</strong> – Next-generation sequencing using melanoma-specific gene panels is increasingly used for the genomic characterization of melanoma, including presence or absence of <em>BRAF</em> mutations; <em>TERT</em> promoter mutations; and the presence of kinase fusions involving <em>MAP3K8</em>, <em>RET</em>, <em>ALK</em>, <em>BRAF</em>, <em>NTRK</em>, and <em>ROS1 </em>[<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluorescence in situ hybridization</strong> – The commercial fluorescence in situ hybridization (FISH) tests and those used in research settings utilize a variety of probes to identify copy number gains and losses in melanoma and Spitz tumors. Some of the probes that identify copy number alterations include chromosomes 6p25, 6q23, 11q13, 9p21, and 8q24 [<a href="#rid53">53</a>]. It is often helpful to first examine for 9p21 deletions. Since this region contains the <em>CDKN2A</em> gene, which encodes P16, immunohistochemistry staining for p16 can be performed to confirm expression and therefore lack of homozygous deletion. Complete absence of p16 expression can be due to homozygous deletion or inactivating mutations, or a combination of both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparative genomic hybridization</strong> – Comparative genomic hybridization (CGH) allows detection of amplifications and deletions of smaller regions of DNA along the lengths of all chromosomes. CGH analysis typically shows copy number alterations of whole chromosomes in proliferative nodules in congenital nevi, whereas copy number variations in regions or segments of chromosomes are observed in melanomas arising in association with giant congenital nevi [<a href="#rid54">54</a>].</p><p></p><p class="headingAnchor" id="H306103079"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Imaging is typically reserved for evaluation of regional and distant disease spread for cases with deep tumor involvement. In adults, ultrasound has been proposed as an alternative to sampling the sentinel lymph node (SLN), although studies have provided inconsistent results. One study including 716 patients with melanoma participating in the Multicenter Selective Lymphadenectomy Trials-I and -II found that the sensitivity of routine preoperative high-resolution targeted ultrasonography to detect a positive node was low (24.3 percent, 95% CI 19.5-28.7 percent), suggesting that the routine use of this technique cannot be used reliably as an alternative to sentinel lymph node biopsy (SLNB) [<a href="#rid55">55</a>]. In contrast, some European centers have demonstrated value of routine high-resolution ultrasound examination of the regional node field in the detection of nodal recurrence among patients who did not have SLNB or had positive biopsy without completion lymph node dissection [<a href="#rid56">56</a>].</p><p>There are no standards for imaging pediatric melanoma, and in many cases, adult recommendations are followed. In one study, extensive pretreatment imaging with computerized tomography (CT), MRI, and positron emission tomography (PET) followed by clinical and intensive radiographic follow-up with CT and MRI suggests that children with spitzoid melanocytic lesions who lack <em>TERT</em> promoter mutations do not require extensive imaging at diagnosis or follow-up, given the very low risk of recurrence [<a href="#rid57">57</a>].</p><p>Brain metastases are best evaluated with MRI. Lung and liver metastases are best evaluated by CT. PET imaging is not routinely utilized, due to low rates of detection of metastatic disease and high false-positive rates associated with inflammation and presence of "brown fat" that is typical of younger patients.</p><p class="headingAnchor" id="H51145297"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of melanoma in children includes a variety of cutaneous lesions, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common or dysplastic nevi</strong> – These nevi present as pigmented papules and macules that may be characteristically round and symmetric (common nevi  (<a class="graphic graphic_picture graphicRef81931" href="/z/d/graphic/81931.html" rel="external">picture 5</a>)) or include clinically atypical features of asymmetry, border irregularity, color variegation, or large diameter (atypical nevi  (<a class="graphic graphic_picture graphicRef70320" href="/z/d/graphic/70320.html" rel="external">picture 6</a>)). Nevi are present in nearly all pediatric patients, and their number increases over the first three decades of life, with a peak occurring during childhood and adolescence. Histologically, these lesions lack criteria for melanoma. These lesions are expected to bleed only with trauma, and unexplained bleeding should be investigated further. (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)"</a> and  <a class="medical medical_review" href="/z/d/html/13519.html" rel="external">"Atypical (dysplastic) nevi"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spitz nevi and atypical Spitz tumors</strong> – These pigmented  (<a class="graphic graphic_picture graphicRef68392" href="/z/d/graphic/68392.html" rel="external">picture 7</a>) or pink papules  (<a class="graphic graphic_picture graphicRef85817" href="/z/d/graphic/85817.html" rel="external">picture 8</a>) are more common among young pediatric patients. Classic Spitz nevi are typically monitored clinically without biopsy or intervention, while those with concerning features on clinical or dermoscopic examination should be biopsied for histopathologic evaluation [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/13523.html" rel="external">"Spitz nevus and atypical Spitz tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blue nevi</strong> – Blue nevi are dark blue-gray papules  (<a class="graphic graphic_picture graphicRef95262" href="/z/d/graphic/95262.html" rel="external">picture 9</a>) and macules that may raise concern due to their characteristic dark color, corresponding to the presence of melanocytes deeper in the dermis. (See  <a class="medical medical_review" href="/z/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Blue nevi'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proliferative nodules</strong> – Proliferative nodules may appear as papules within larger congenital nevi and have atypical histology  (<a class="graphic graphic_picture graphicRef94602" href="/z/d/graphic/94602.html" rel="external">picture 10</a>) but reassuring genomic studies [<a href="#rid59">59</a>]. In a comparison of proliferative nodules and lethal melanomas arising in congenital nevi of children, one study reported that proliferative nodules more frequently arise from dermis, occur in multiple sites instead of one single focus, and have infrequent ulceration (3 of 22 proliferative nodules versus 2 of 2 lethal melanomas) [<a href="#rid60">60</a>]. These authors also reported that histologically proliferative nodules had lower mitotic rates (&lt;5/mm<sup>2</sup>) than that generally seen in melanomas. Proliferative nodules more often have whole chromosomal aberrations, whereas lethal melanomas more often have copy number aberrations of 6p25 without gains of the long arm of chromosome 6 [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/4847.html" rel="external">"Congenital melanocytic nevi"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pyogenic granulomas</strong> – Pyogenic granuloma, also called lobular capillary hemangioma, is a benign vascular tumor that presents as a growing pink or red papule that can bleed, simulating an amelanotic melanoma. Histology shows a distinct vascular proliferation. (See  <a class="medical medical_review" href="/z/d/html/13736.html" rel="external">"Pyogenic granuloma (lobular capillary hemangioma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warts</strong> – Warts are viral papules that are often characterized by hyperkeratosis and/or visible pinpoint capillary vessels. They can arise on cutaneous or mucosal surfaces and within congenital melanocytic nevi. The presence of multiple lesions and characteristic clinical features suggests the diagnosis. Histopathology can confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/4029.html" rel="external">"Cutaneous warts (common, plantar, and flat warts)"</a>.)</p><p></p><p class="headingAnchor" id="H51145303"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The staging system and management of pediatric melanoma is the same as for adult melanoma. (See  <a class="medical medical_review" href="/z/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H51145309"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>The first-line therapy for pediatric melanoma is wide local excision to the deep fascia. The margin size depends on the thickness of melanoma and on whether the anatomic location permits removal with the designated/recommended margins, which are the same as for melanoma in adults. Margins of excision specific to pediatric patients with melanoma have not been defined. While in most cases adult guidelines are followed, in younger children consideration can be given to narrower margins of excision than those used in adults. Thin (&lt;1 mm) pediatric melanomas typically do not require further treatment beyond wide excision, though the children will enter a monitoring phase with regular skin and lymph node examinations. (See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p class="headingAnchor" id="H51145315"><span class="h2">Sentinel lymph node biopsy</span><span class="headingEndMark"> — </span>Lymphatic mapping and sentinel lymph node biopsy (SLNB) is controversial in pediatric patients. This is a procedure that allows identification of lymph node micrometastases and pathologic staging of melanoma involving the regional lymph node basin. In adults, randomized trials have demonstrated the utility of this method in prognostication and risk stratification [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma", section on 'SLNB timing and technique'</a>.)</p><p>The controversy in the use of SLNB in pediatric patients stems from data indicating that younger patients, who in most cases have spitzoid melanomas (or indeterminate or borderline tumors), have higher rates of positive sentinel lymph node (SLN) compared with adult patients and that positivity does not predict an aggressive clinical course [<a href="#rid62">62</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One study reporting on a series of 109 patients &lt;18 years found that SLN positivity did not predict prognosis or outcome in pediatric melanoma [<a href="#rid63">63</a>]. In this study, 57 patients had a SLNB, with a positive result in 52 percent of patients under age 10 years and 26 percent of patients aged 10 to 17 years. In addition to younger age, tumor thickness &gt;2 mm was also associated with SLN positivity. In this cohort, none of the patients under age 10 years died from melanoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor thickness was associated with SLN positivity in a separate series of 126 patients &lt;21 years with melanoma [<a href="#rid64">64</a>]. Of 62 patients who underwent SLNB, 29 percent were positive, and positivity was correlated with tumor thickness. The five-year melanoma-specific survival was 78 percent for patients with positive SLN compared with 97 percent for those with negative SLN. These rates are similar to those reported for the corresponding stages in the American Joint Committee on Cancer (AJCC) seventh edition staging system, which predominantly included adults [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 541 patients with atypical Spitz tumors who were followed for a mean of 59.4 months, 56 percent underwent a sentinel node biopsy and 39 percent had a positive node. Eighty-two percent of these patients had a completion node dissection, and 19 percent had additional positive nodes. Despite this, 99 percent of the patients with atypical Spitz tumors and a positive sentinel node who were treated with surgery alone were alive at a median follow-up of 59 months [<a href="#rid66">66</a>].</p><p></p><p>Thus, the decision to pursue SLNB should be made for the individual patient, taking into consideration the patient's age, histopathologic and molecular diagnosis, anatomic location, lymph drainage, and risk of false negativity and false positivity. False positivity may be due to the presence of nevus cells in the lymph node [<a href="#rid67">67</a>]. For pediatric patients with a diagnosis of melanoma that has qualifying features per adult data, SLNB is recommended. Tumors that are indeterminate or spitzoid melanomas in children diagnosed before age 11 require additional consideration.</p><p>Although completion dissection of all involved nodal basins previously was considered the standard treatment for patients with a positive SLNB, this approach is no longer recommended. The Multicenter Selective Lymphadenectomy Trial-II (MSLT-II) comparing immediate completion lymph node dissection with observation followed by lymph node dissection in the event of a regional lymph node recurrence did not demonstrate any improvement in melanoma-specific survival or distant metastasis-free survival for patients who underwent completion lymph node dissection [<a href="#rid68">68</a>].</p><p>If the SLNB is positive, surveillance of the nodal basins with clinical observation and serial ultrasound imaging is appropriate. (See  <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma", section on 'Subsequent management'</a>.)</p><p>If nonsentinel nodes become enlarged and are histologically proven to be involved, therapeutic lymph node dissection may be warranted to prevent the development of bulky adenopathy, although the procedure has no impact on survival. Lymph node dissection confers significant morbidity and complication risk. In a series of 125 pediatric patients, complications occurred in 52 percent of inguinal dissections and 17 percent of axillary dissections [<a href="#rid69">69</a>]. Lymphedema occurred in 2 percent of patients who had undergone SLNB alone compared with 20 percent when completion dissection was performed. (See  <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H51145321"><span class="h2">Adjuvant therapy</span><span class="headingEndMark"> — </span>As in adults, adjuvant therapy has generally been used for patients with localized disease at increased risk for disease dissemination due to regional lymph node disease or a high-risk primary tumor. Data on the efficacy of adjuvant therapy in children and adolescents are scant [<a href="#rid70">70</a>]. Adjuvant targeted therapies against MAPK pathway have proven to be highly effective in high-risk resected adult melanoma [<a href="#rid71">71</a>] and may be considered for patients whose tumors demonstrate relevant genomic alterations, such as a <em>BRAF</em> V600E mutation [<a href="#rid72">72,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p>Immunotherapy with checkpoint inhibitors, such as <a class="drug drug_pediatric" data-topicid="113354" href="/z/d/drug information/113354.html" rel="external">pembrolizumab</a> and <a class="drug drug_pediatric" data-topicid="115765" href="/z/d/drug information/115765.html" rel="external">nivolumab</a>, have produced improvements in relapse survival in adult patients with high-risk resected disease, and these therapies have been studied in pediatric patients, providing a safe and rationale alternative to adjuvant therapies in selected patients with pediatric melanoma [<a href="#rid74">74-78</a>]. (See  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p class="headingAnchor" id="H1465782217"><span class="h2">Metastatic melanoma</span><span class="headingEndMark"> — </span>Our approach for pediatric and adolescent patients is to enroll patients in formal clinical protocols whenever possible or to pattern therapy after that in adults. (See  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma", section on 'Pediatric and adolescent patients'</a> and  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p class="headingAnchor" id="H59260595"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Although interventions to reduce individual exposure to ultraviolet (UV) light are universally recommended for the primary prevention of melanoma, their impact on melanoma risk among patients with giant congenital nevi or prepubertal cases is uncertain. Nonetheless, since childhood and adolescence are critical times to establish and practice sun protection behaviors that can modify future melanoma risk, patients, parents, and caregivers should be educated to adopt "safe sun" behaviors.</p><p>Based on evidence of benefit of behavioral counseling interventions on children's parents, adolescents, and young adults, the United States Preventive Services Task Force (USPSTF) recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to UV radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer [<a href="#rid79">79,80</a>].</p><p>Sun protection measures include minimizing outdoor exposure between 10 AM and 2 PM; avoiding indoor tanning; wearing protective clothing and large hats; and using broad-spectrum sunscreens, including physical blockers such as <a class="drug drug_pediatric" data-topicid="12893" href="/z/d/drug information/12893.html" rel="external">zinc oxide</a> and titanium dioxide, which are not absorbed by the skin, and reapplying sunscreen every few hours, as needed, to prevent sunburn. (See  <a class="medical medical_review" href="/z/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p class="headingAnchor" id="H51145345"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>As for adult melanoma, the most important predictors of prognosis for non-Spitz pediatric melanoma are tumor thickness, presence of ulceration, and stage at diagnosis [<a href="#rid3">3,81,82</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The analysis of an international registry of 365 patients aged 1 to 21 years with invasive melanoma reported a 10-year overall survival rate of 81 percent; the survival rate was 100 percent for patients up to age 10 years, 70 percent for patients aged 10 to 15 years, and 80 percent for patients aged 15 to 20 years [<a href="#rid3">3</a>]. Tumor thickness at diagnosis was strongly associated with the 10-year survival, with 97 percent survival among patients with lesions &lt;1 mm and 80 percent among patients with lesions &gt;4 mm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an international cohort of 62 children and 452 adolescents treated for invasive melanoma between 2000 and 2014, the 10-year recurrence-free survival was 91.5 percent (95% CI 82.4-100) in children and 86.4 percent (95% CI 82.7-90.3) in adolescents [<a href="#rid83">83</a>]. Among adolescents, head and neck location, Breslow thickness &gt;4 mm, and ulceration were associated with poorer survival.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An Italian prospective registry study of 54 patients younger than 18 years with melanoma found an overall five-year survival of 85 percent. Survival was correlated with tumor stage and ulceration [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 100 patients aged 11 to 22 years with conventional (superficial spreading and nodular) melanomas followed up for a median of 7.6 years, 16 patients developed a recurrence, and 8 eventually died of melanoma [<a href="#rid84">84</a>]. The 20-year overall survival, recurrence rate, and melanoma-specific mortality were 77, 34, and 20 percent, respectively. Of 21 patients who underwent sentinel lymph node biopsy, all were negative, and none developed a recurrence.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review and individual patient meta-analysis that included 1002 children with melanoma, 108 patients (median age 8 years [range 4 to 12]) had spitzoid/spindle cell melanomas with a median Breslow thickness of 3.3 mm [<a href="#rid85">85</a>]. Seventy-three (67 percent) developed metastasis (73 percent nodal), and 12 percent died of melanoma. In contrast, the mortality rates for superficial spreading (n = 210) and nodular melanoma (n = 139) were 15 and 45 percent, respectively.</p><p></p><p>Fatal outcome from pediatric melanoma can occur with a variety of presenting types and is more common among patients diagnosed with melanoma during adolescence than in childhood [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H51145351"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Pediatric melanoma follow-up protocols align with the adult recommendations for regular total-body skin examination and lymph node surveillance to evaluate for recurrence or metastasis. Surveillance with ionizing radiation (CT or positron emission tomography [PET] scans) is generally pursued less aggressively than in adults due to concerns about the cumulative impact of radiation exposure [<a href="#rid86">86</a>]. Typically, physical examination with special attention to regional recurrences is performed every three months for one year, then every six months for five years, followed by annual exams thereafter. (See  <a class="medical medical_review" href="/z/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H831956438"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H51145357"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> <strong>and risk factors</strong> – Pediatric melanoma is rare, representing only 1 to 4 percent of all melanomas, with an annual incidence estimated at six per million individuals. Children and adults share similar risk factors for developing melanoma, including genetic factors (eg, family history of melanoma, light phenotype, high nevus counts, congenital nevi, high-risk germline mutations) and environmental factors (eg, excessive ultraviolet exposure from direct sunlight or indoor tanning, history of sunburns, immunosuppression). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – The clinical presentation of melanoma in children often does not conform to the conventional ABCDE criteria (<strong>a</strong>symmetry, <strong>b</strong>order irregularity, <strong>c</strong>olor variegation, large <strong>d</strong>iameter, and <strong>e</strong>volution). Especially in prepubertal children, melanoma may simulate a banal nevus, pyogenic granuloma, or common wart. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of melanoma in children is challenging due to its rarity and often atypical clinical presentation. It requires a high index of suspicion based upon history, clinical, and dermoscopic findings. When melanoma is suspected, the preferred biopsy is an excisional biopsy deep to the subcutaneous fat with 2 mm rim of normal-appearing skin. This provides an adequate specimen for histopathologic examination. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The staging system of pediatric melanoma is the same as for adult melanoma. The decision to pursue sentinel lymph node biopsy should be made for the individual patient, taking into consideration the patient's age, clinical context, subtype of melanoma and certainty in its diagnosis, anatomic location, lymph drainage, prognostic information desired, and risk of false-positive and false-negative results. (See <a class="local">'Sentinel lymph node biopsy'</a> above and  <a class="medical medical_review" href="/z/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The first-line therapy for pediatric melanoma is wide local excision to the deep fascia. The margin size depends on the thickness of melanoma and on whether the anatomic location permits removal with the designated margins. Thin (&lt;1 mm) pediatric melanomas typically do not require further treatment beyond wide excision. Once excised, children will enter a monitoring phase with regular skin and lymph node examinations. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Austin MT, Xing Y, Hayes-Jordan AA, et al. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg 2013; 48:2207.</a></li><li><a class="nounderline abstract_t">Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005; 23:4735.</a></li><li><a class="nounderline abstract_t">Averbook BJ, Lee SJ, Delman KA, et al. Pediatric melanoma: analysis of an international registry. Cancer 2013; 119:4012.</a></li><li><a class="nounderline abstract_t">SPITZ S. Melanomas of childhood. Am J Pathol 1948; 24:591.</a></li><li class="breakAll">National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review (CSR) 1975-2014. www.seer.cancer.gov/csr/1975_2014/ (Accessed on February 07, 2018).</li><li><a class="nounderline abstract_t">Rajput A, Faizi SA, Nir I, et al. Pediatric melanoma in New Mexico American Indians, Hispanics, and non-Hispanic whites, 1981-2009. Am J Surg 2014; 207:412.</a></li><li><a class="nounderline abstract_t">Wong JR, Harris JK, Rodriguez-Galindo C, Johnson KJ. Incidence of childhood and adolescent melanoma in the United States: 1973-2009. Pediatrics 2013; 131:846.</a></li><li><a class="nounderline abstract_t">Campbell LB, Kreicher KL, Gittleman HR, et al. Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States. J Pediatr 2015; 166:1505.</a></li><li><a class="nounderline abstract_t">Baade PD, Youlden DR, Valery PC, et al. Trends in incidence of childhood cancer in Australia, 1983-2006. Br J Cancer 2010; 102:620.</a></li><li><a class="nounderline abstract_t">Karlsson PM, Fredrikson M. Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken. Int J Cancer 2007; 121:323.</a></li><li><a class="nounderline abstract_t">Cordoro KM, Gupta D, Frieden IJ, et al. Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol 2013; 68:913.</a></li><li><a class="nounderline abstract_t">Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One 2013; 8:e59709.</a></li><li><a class="nounderline abstract_t">Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272.</a></li><li><a class="nounderline abstract_t">Pellegrini C, Botta F, Massi D, et al. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. Lancet Child Adolesc Health 2019; 3:332.</a></li><li><a class="nounderline abstract_t">Pellegrini C, Raimondi S, Di Nardo L, et al. Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. J Eur Acad Dermatol Venereol 2022; 36:213.</a></li><li><a class="nounderline abstract_t">Braam KI, Overbeek A, Kaspers GJ, et al. Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review. Pediatr Blood Cancer 2012; 58:665.</a></li><li><a class="nounderline abstract_t">Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006; 155:1.</a></li><li><a class="nounderline abstract_t">Schaffer JV. Update on melanocytic nevi in children. Clin Dermatol 2015; 33:368.</a></li><li><a class="nounderline abstract_t">Vourc'h-Jourdain M, Martin L, Barbarot S, aRED. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68:493.</a></li><li><a class="nounderline abstract_t">Bett BJ. Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. J Am Acad Dermatol 2005; 52:793.</a></li><li><a class="nounderline abstract_t">Watt AJ, Kotsis SV, Chung KC. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Reconstr Surg 2004; 113:1968.</a></li><li><a class="nounderline abstract_t">Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies. Clin Dermatol 2010; 28:293.</a></li><li><a class="nounderline abstract_t">Kinsler VA, O'Hare P, Bulstrode N, et al. Melanoma in congenital melanocytic naevi. Br J Dermatol 2017; 176:1131.</a></li><li><a class="nounderline abstract_t">Bartenstein DW, Kelleher CM, Friedmann AM, et al. Contrasting features of childhood and adolescent melanomas. Pediatr Dermatol 2018; 35:354.</a></li><li><a class="nounderline abstract_t">Bahrami A, Barnhill RL. Pathology and genomics of pediatric melanoma: A critical reexamination and new insights. Pediatr Blood Cancer 2018; 65.</a></li><li><a class="nounderline abstract_t">Kim DJ, Yuan TA, Chen PC, et al. Pediatric melanoma in the Hispanic population: An analysis of institutional and national data. Pediatr Dermatol 2021; 38:1102.</a></li><li><a class="nounderline abstract_t">Villa A, Woo SB. Leukoplakia-A Diagnostic and Management Algorithm. J Oral Maxillofac Surg 2017; 75:723.</a></li><li><a class="nounderline abstract_t">Raghavan SS, Peternel S, Mully TW, et al. Spitz melanoma is a distinct subset of spitzoid melanoma. Mod Pathol 2020; 33:1122.</a></li><li><a class="nounderline abstract_t">Elder DE, Bastian BC, Cree IA, et al. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Arch Pathol Lab Med 2020; 144:500.</a></li><li><a class="nounderline abstract_t">Hawryluk EB, Moustafa D, Bartenstein D, et al. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol 2020; 83:1274.</a></li><li><a class="nounderline abstract_t">Pappo AS, McPherson V, Pan H, et al. A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions. Cancer 2021; 127:3825.</a></li><li><a class="nounderline abstract_t">Richardson SK, Tannous ZS, Mihm MC Jr. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol 2002; 47:77.</a></li><li><a class="nounderline abstract_t">Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003; 21:2179.</a></li><li><a class="nounderline abstract_t">Valenzano Menada M, Moioli M, Garaventa A, et al. Spontaneous regression of transplacental metastases from maternal melanoma in a newborn: case report and review of the literature. Melanoma Res 2010; 20:443.</a></li><li><a class="nounderline abstract_t">Lu C, Zhang J, Nagahawatte P, et al. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol 2015; 135:816.</a></li><li><a class="nounderline abstract_t">Charbel C, Fontaine RH, Malouf GG, et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. J Invest Dermatol 2014; 134:1067.</a></li><li><a class="nounderline abstract_t">Lee S, Barnhill RL, Dummer R, et al. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. Sci Rep 2015; 5:11200.</a></li><li><a class="nounderline abstract_t">Newman S, Fan L, Pribnow A, et al. Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nat Med 2019; 25:597.</a></li><li><a class="nounderline abstract_t">Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014; 5:3116.</a></li><li><a class="nounderline abstract_t">Dimonitsas E, Liakea A, Sakellariou S, et al. An update on molecular alterations in melanocytic tumors with emphasis on Spitzoid lesions. Ann Transl Med 2018; 6:249.</a></li><li><a class="nounderline abstract_t">Wilmott JS, Johansson PA, Newell F, et al. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. Int J Cancer 2019; 144:1049.</a></li><li><a class="nounderline abstract_t">Carrera C, Scope A, Dusza SW, et al. Clinical and dermoscopic characterization of pediatric and adolescent melanomas: Multicenter study of 52 cases. J Am Acad Dermatol 2018; 78:278.</a></li><li><a class="nounderline abstract_t">Mitkov M, Chrest M, Diehl NN, et al. Pediatric melanomas often mimic benign skin lesions: A retrospective study. J Am Acad Dermatol 2016; 75:706.</a></li><li><a class="nounderline abstract_t">Haliasos EC, Kerner M, Jaimes N, et al. Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions. Pediatr Dermatol 2013; 30:281.</a></li><li><a class="nounderline abstract_t">Silverberg NB, McCuaig CC. Melanoma in childhood: changing our mind-set. Cutis 2013; 92:217.</a></li><li><a class="nounderline abstract_t">Hawryluk EB, Sober AJ, Piris A, et al. Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. J Am Acad Dermatol 2012; 67:727.</a></li><li class="breakAll">Barnhill RL, Spatz A. Congenital melanocytic nevi and associated neoplasms, congenital and childhood melanoma. In: Pathology of Melanocytic Nevi and Melanoma, Barnhill RL, Piepkorn M, Busam KJ (Eds), Springer Verlag, 2014.</li><li><a class="nounderline abstract_t">Tosti A, Piraccini BM, Cagalli A, Haneke E. In situ melanoma of the nail unit in children: report of two cases in fair-skinned Caucasian children. Pediatr Dermatol 2012; 29:79.</a></li><li><a class="nounderline abstract_t">Neuhold JC, Friesenhahn J, Gerdes N, Krengel S. Case reports of fatal or metastasizing melanoma in children and adolescents: a systematic analysis of the literature. Pediatr Dermatol 2015; 32:13.</a></li><li><a class="nounderline abstract_t">Benton S, Zhao J, Zhang B, et al. Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. Am J Surg Pathol 2021; 45:1597.</a></li><li><a class="nounderline abstract_t">Quan VL, Zhang B, Zhang Y, et al. Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms. J Invest Dermatol 2020; 140:1599.</a></li><li><a class="nounderline abstract_t">Hillen LM, Van den Oord J, Geybels MS, et al. Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management. Front Med (Lausanne) 2018; 5:344.</a></li><li><a class="nounderline abstract_t">Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol 2013; 37:676.</a></li><li><a class="nounderline abstract_t">Bastian BC, Xiong J, Frieden IJ, et al. Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas. Am J Pathol 2002; 161:1163.</a></li><li><a class="nounderline abstract_t">Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol 2009; 27:5614.</a></li><li><a class="nounderline abstract_t">Krüger U, Kretschmer L, Thoms KM, et al. Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection compared with clinical examination alone: a study on 433 patients. Melanoma Res 2011; 21:457.</a></li><li><a class="nounderline abstract_t">Halalsheh H, Kaste SC, Navid F, et al. The role of routine imaging in pediatric cutaneous melanoma. Pediatr Blood Cancer 2018; 65:e27412.</a></li><li><a class="nounderline abstract_t">Tlougan BE, Orlow SJ, Schaffer JV. Spitz nevi: beliefs, behaviors, and experiences of pediatric dermatologists. JAMA Dermatol 2013; 149:283.</a></li><li><a class="nounderline abstract_t">Phadke PA, Rakheja D, Le LP, et al. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases. Am J Surg Pathol 2011; 35:656.</a></li><li><a class="nounderline abstract_t">Yélamos O, Arva NC, Obregon R, et al. A comparative study of proliferative nodules and lethal melanomas in congenital nevi from children. Am J Surg Pathol 2015; 39:405.</a></li><li><a class="nounderline abstract_t">Stebbins WG, Garibyan L, Sober AJ. Sentinel lymph node biopsy and melanoma: 2010 update Part I. J Am Acad Dermatol 2010; 62:723.</a></li><li><a class="nounderline abstract_t">Howman-Giles R, Shaw HM, Scolyer RA, et al. Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients. Ann Surg Oncol 2010; 17:138.</a></li><li><a class="nounderline abstract_t">Moore-Olufemi S, Herzog C, Warneke C, et al. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg 2011; 253:1211.</a></li><li><a class="nounderline abstract_t">Han D, Zager JS, Han G, et al. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol 2012; 19:3888.</a></li><li><a class="nounderline abstract_t">Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199.</a></li><li><a class="nounderline abstract_t">Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Oncol 2014; 15:e178.</a></li><li><a class="nounderline abstract_t">Davis J, Patil J, Aydin N, et al. Capsular nevus versus metastatic malignant melanoma - a diagnostic dilemma. Int J Surg Case Rep 2016; 29:20.</a></li><li><a class="nounderline abstract_t">Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211.</a></li><li><a class="nounderline abstract_t">Palmer PE 3rd, Warneke CL, Hayes-Jordan AA, et al. Complications in the surgical treatment of pediatric melanoma. J Pediatr Surg 2013; 48:1249.</a></li><li><a class="nounderline abstract_t">Raef HS, Friedmann AM, Hawryluk EB. Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. Paediatr Drugs 2019; 21:71.</a></li><li><a class="nounderline abstract_t">Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020; 383:1139.</a></li><li><a class="nounderline abstract_t">Bouffet E, Geoerger B, Moertel C, et al. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma. J Clin Oncol 2023; 41:664.</a></li><li><a class="nounderline abstract_t">Trippett T, Toledano H, Campbell Hewson Q, et al. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study. Target Oncol 2022; 17:283.</a></li><li><a class="nounderline abstract_t">Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377:1824.</a></li><li><a class="nounderline abstract_t">Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378:1789.</a></li><li><a class="nounderline abstract_t">Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022; 399:1718.</a></li><li><a class="nounderline abstract_t">Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:541.</a></li><li><a class="nounderline abstract_t">Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol 2020; 21:121.</a></li><li><a class="nounderline abstract_t">Henrikson NB, Morrison CC, Blasi PR, et al. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319:1143.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 319:1134.</a></li><li><a class="nounderline abstract_t">Ferrari A, Bisogno G, Cecchetto G, et al. Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. J Pediatr 2014; 164:376.</a></li><li><a class="nounderline abstract_t">Fernandez JM, Koblinski JE, Dahak S, et al. Gender differences in pediatric and adolescent melanoma: A retrospective analysis of 4645 cases. J Am Acad Dermatol 2024; 90:280.</a></li><li><a class="nounderline abstract_t">El Sharouni MA, Rawson RV, Potter AJ, et al. Melanomas in children and adolescents: Clinicopathologic features and survival outcomes. J Am Acad Dermatol 2023; 88:609.</a></li><li><a class="nounderline abstract_t">Stanelle EJ, Busam KJ, Rich BS, et al. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis. J Pediatr Surg 2015; 50:1019.</a></li><li><a class="nounderline abstract_t">Pampena R, Piccolo V, Muscianese M, et al. Melanoma in children: A systematic review and individual patient meta-analysis. J Eur Acad Dermatol Venereol 2023; 37:1758.</a></li><li><a class="nounderline abstract_t">McHugh K, Roebuck DJ. Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer 2014; 61:3.</a></li></ol></div><div id="topicVersionRevision">Topic 101324 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24210187" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034049" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24022819" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pediatric melanoma: analysis of an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18859360" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Melanomas of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18859360" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Melanomas of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24581766" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pediatric melanoma in New Mexico American Indians, Hispanics, and non-Hispanic whites, 1981-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23589817" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of childhood and adolescent melanoma in the United States: 1973-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866386" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051948" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Trends in incidence of childhood cancer in Australia, 1983-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17372908" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous malignant melanoma in children and adolescents in Sweden, 1993-2002: the increasing trend is broken.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395590" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric melanoma: results of a large cohort study and proposal for modified ABCD detection criteria for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23573208" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Spectrum and risk of neoplasia in Werner syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800318" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30872112" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34664323" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22232079" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792745" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Melanoma risk in congenital melanocytic naevi: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25889140" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Update on melanocytic nevi in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182059" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858468" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253185" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of melanoma arising in large congenital melanocytic nevi: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20541682" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Congenital melanocytic nevi-when to worry and how to treat: Facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28078671" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Melanoma in congenital melanocytic naevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29569376" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Contrasting features of childhood and adolescent melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28895292" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pathology and genomics of pediatric melanoma: A critical reexamination and new insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486809" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pediatric melanoma in the Hispanic population: An analysis of institutional and national data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27865803" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Leukoplakia-A Diagnostic and Management Algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31900433" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spitz melanoma is a distinct subset of spitzoid melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32057276" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622142" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A retrospective multicenter study of fatal pediatric melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34228365" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A prospective, comprehensive registry that integrates the molecular analysis of pediatric and adolescent melanocytic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077586" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775744" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20948450" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Spontaneous regression of transplacental metastases from maternal melanoma in a newborn: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25268584" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The genomic landscape of childhood and adolescent melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24129063" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061100" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30833747" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24445538" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30069451" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An update on molecular alterations in melanocytic tumors with emphasis on Spitzoid lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30178487" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29024734" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical and dermoscopic characterization of pediatric and adolescent melanomas: Multicenter study of 52 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27430613" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pediatric melanomas often mimic benign skin lesions: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252411" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dermoscopy for the pediatric dermatologist part III: dermoscopy of melanocytic lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24343205" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Melanoma in childhood: changing our mind-set.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22521204" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22521204" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575049" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : In situ melanoma of the nail unit in children: report of two cases in fair-skinned Caucasian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487565" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Case reports of fatal or metastasizing melanoma in children and adolescents: a systematic analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34757982" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004563" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Integrating Next-Generation Sequencing with Morphology Improves Prognostic and Biologic Classification of Spitz Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30619857" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388126" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368190" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Genetic changes in neoplasms arising in congenital melanocytic nevi: differences between nodular proliferations and melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786669" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21730878" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lymph node ultrasound during melanoma follow-up significantly improves metastasis detection compared with clinical examination alone: a study on 433 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30124237" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The role of routine imaging in pediatric cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23553063" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Spitz nevi: beliefs, behaviors, and experiences of pediatric dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436676" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517953" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A comparative study of proliferative nodules and lethal melanomas in congenital nevi from children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398810" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sentinel lymph node biopsy and melanoma: 2010 update Part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19672660" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sentinel lymph node biopsy in pediatric and adolescent cutaneous melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21451389" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22864798" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The unique clinical characteristics of melanoma diagnosed in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917835" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Final version of 2009 AJCC melanoma staging and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694641" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27810606" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Capsular nevus versus metastatic malignant melanoma - a diagnostic dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28591523" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845614" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Complications in the surgical treatment of pediatric melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30924056" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32877599" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375115" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35715627" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28891423" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29658430" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35367007" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32192573" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31812554" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29558557" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29558558" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252782" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37802183" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Gender differences in pediatric and adolescent melanoma: A retrospective analysis of 4645 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36509217" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Melanomas in children and adolescents: Clinicopathologic features and survival outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819019" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37210654" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Melanoma in children: A systematic review and individual patient meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24108532" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
